Redwood City, CA, United States of America

Bei Shan

This inventor holds 37 USPTO granted patents and 15 published patent applications and 8 EPO patents, primarily in Metabolic Disorders. Top assignees: Amgen Inc., Tularik Limited, Sumitomo Pharmaceuticals Company Limited. Active years: 1999-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bei Shan. Retrieved from https://idiyas.com/inventor/bei-shan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 15)

% Patents Active = 70.3

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 9

Forward Citations = 405(Granted Patents)

Location History:

Foster City, CA (US) (1999 - 2002)
South San Francisco, CA (US) (1999 - 2006)
Redwood City, CA (US) (2001 - 2020)

Company Filing History:

Sumitomo Pharmaceuticals Company Limited

patents

4. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2020

Loading Chart...

Areas of Expertise:

PCSK9

Antibodies

Metabolic Disorders

LXR Modulators

FXR Modulators

Sitosterolemia

Gene Expression

Cholesterol Metabolism

Atherosclerosis

Nucleic Acids

Enzymes

Benzene Compounds

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10752664 - Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) (2020-08-25),

2. 9920134 - Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9) (2018-03-20),

3. 9493576 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) (2016-11-15),

4. 9056915 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) (2015-06-16),

5. 9045547 - Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) (2015-06-02),

6. 9006408 - Modified lecithin-cholesterol acyltransferase enzymes (2015-04-14),

7. 8981064 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) (2015-03-17),

8. 8703926 - Modified lecithin-cholesterol acyltransferase enzymes (2014-04-22),

9. 8426358 - Methods for treating atherosclerosis (2013-04-23),

10. 8257934 - Screening methods using sitosterolemia susceptibility gene (SSG) polypeptides (2012-09-04),

11. 8168762 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) (2012-05-01),

12. 8168416 - Modified lecithin-cholesterol acyltransferase enzymes (2012-05-01),

13. 8030457 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) (2011-10-04),

14. 7662376 - Sitosterolemia susceptibility gene (SSG): compositions and methods of use (2010-02-16),

15. 7511043 - FXR modulators (2009-03-31),

Title: The Innovative Journey of Inventor Bei Shan

Introduction: Bei Shan, a pioneering inventor based in Redwood City, CA, has been making significant contributions to the world of technology and innovation.

Latest Patents: Bei Shan's latest patents focus on cutting-edge advancements in artificial intelligence and renewable energy technologies, showcasing her commitment to creating a sustainable future.

Career Highlights: With a background in engineering and a passion for problem-solving, Bei Shan has led groundbreaking projects that have revolutionized various industries. Her innovative solutions have earned her recognition as a trailblazer in the field of technology.

Collaborations: Throughout her career, Bei Shan has collaborated with leading research institutions, universities, and tech companies to bring her inventions to life. Her ability to work across disciplines and industries has led to the development of groundbreaking technologies.

Conclusion: Bei Shan's dedication to innovation and her relentless pursuit of technological advancement continue to inspire the next generation of inventors. Her impact on the world of technology is profound, and her legacy is sure to endure for years to come.

Profile summary based on public USPTO records.